Education
About Us
Working with TipRanks
Follow Us
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H (HK:8189)
:8189
Total Valuation
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has a market cap or net worth of HK$640.17M. The enterprise value is ―.
Market CapHK$640.17M
Enterprise Value―
Share Statistics
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has 1,436,400,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,436,400,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s return on equity (ROE) is -1.26 and return on invested capital (ROIC) is -15.05%.
Return on Equity (ROE)-1.26
Return on Assets (ROA)-0.08
Return on Invested Capital (ROIC)-15.05%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee1.48M
Profits Per Employee-139.85K
Employee Count260
Asset Turnover1.16
Inventory Turnover4.89
Valuation Ratios
The current PE Ratio of Tianjin TEDA Biomedical Engineering Co. Ltd. Class H is ―. Tianjin TEDA Biomedical Engineering Co. Ltd. Class H’s PEG ratio is -0.19.
PE Ratio―
PS Ratio1.41
PB Ratio24.48
Price to Fair Value24.48
Price to FCF-18.81
Price to Operating Cash Flow-7.76
PEG Ratio-0.19
Income Statement
In the last 12 months, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H had revenue of 385.48M and earned -27.80M in profits. Earnings per share was -0.02.
Revenue385.48M
Gross Profit16.97M
Operating Income-28.38M
Pretax Income-38.21M
Net Income-27.80M
EBITDA-20.19M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -98.40M and capital expenditures -834.92K, giving a free cash flow of -99.23M billion.
Operating Cash Flow-98.40M
Free Cash Flow-99.23M
Free Cash Flow per Share-0.07
Dividends & Yields
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.02
52-Week Price Change7.14%
50-Day Moving Average0.37
200-Day Moving Average0.43
Relative Strength Index (RSI)36.94
Average Volume (3m)1.66M
Important Dates
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H upcoming earnings date is Mar 26, 2026, TBA (Not Confirmed).
Last Earnings DateNov 18, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H as a current ratio of 0.84, with Debt / Equity ratio of 116.52%
Current Ratio0.84
Quick Ratio0.57
Debt to Market Cap0.28
Net Debt to EBITDA-6.66
Interest Coverage Ratio-6.20
Taxes
In the past 12 months, Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has paid -221.32K in taxes.
Income Tax-221.32K
Effective Tax Rate>-0.01
Enterprise Valuation
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H EV to EBITDA ratio is -33.53, with an EV/FCF ratio of -23.48.
EV to Sales1.76
EV to EBITDA-33.53
EV to Free Cash Flow-23.48
EV to Operating Cash Flow-25.76
Balance Sheet
Tianjin TEDA Biomedical Engineering Co. Ltd. Class H has HK$186.13M in cash and marketable securities with HK$112.58M in debt, giving a net cash position of HK$73.55M billion.
Cash & Marketable SecuritiesHK$186.13M
Total DebtHK$112.58M
Net CashHK$73.55M
Net Cash Per ShareHK$0.05
Tangible Book Value Per Share<HK$0.01
Margins
Gross margin is 5.98%, with operating margin of -7.36%, and net profit margin of -7.21%.
Gross Margin5.98%
Operating Margin-7.36%
Pretax Margin-9.91%
Net Profit Margin-7.21%
EBITDA Margin-5.24%
EBIT Margin-7.36%
Analyst Forecast
The average price target for Tianjin TEDA Biomedical Engineering Co. Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-5.79%
EPS Growth Forecast-129.73%